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ABSTRACT
The performances of ﬁve commercially available enzyme immunoassays were compared for the
detection of Borrelia burgdorferi IgM and IgG antibodies. Sensitivity was assessed with European serum
samples collected from 45 patients with clinically deﬁned Lyme disease in conjunction with a positive
immunoblot (n = 44) or other serological test (n = 1). Sensitivities for the detection of IgM and IgG with
each test were: Dako IgM 64%; Dako IgG 53%; Serion IgM 89%; and Serion IgG 88%. The Immunetics
assay makes no distinction between IgM and IgG antibodies and had a sensitivity of 91%. Speciﬁcity
was calculated by testing a control group comprising 40 patients with acute Epstein–Barr virus infection,
cytomegalovirus infection, syphilis or rheumatoid factor positivity. The speciﬁcities achieved for each
test were: Dako IgM 78%; Dako IgG 100%; Serion IgM 52%; Serion IgG 92%; and Immunetics 92%. The
discriminatory power between control and patient samples appeared highest for the Immunetics assay.
Between-run variation was comparable for the ﬁve tests and did not exceed 13%. When the Immunetics
assay was used as an initial screening test, with low-titre positive results conﬁrmed by an immunoblot, a
sensitivity of 91% and a speciﬁcity of 100%were achieved. To attain maximal sensitivity, the Serion IgM
and IgG tests were also performed on samples with negative Immunetics results. All positive Serion IgM
and IgG results were also conﬁrmed by immunoblot. In conclusion, the Immunetics assay, based on a
synthetic C6 peptide, can be used reliably as an initial screening test for the serodiagnosis of Lyme
disease.
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INTRODUCTION
Lyme borreliosis is an infectious disease with
multi-organ involvement, including skin, nervous
system, joints and heart [1–7]. The illness is
caused by a tick-transmitted spirochaete, Borrelia
burgdorferi sensu lato, with three subspecies that
are known to be pathogenic to humans: B. burg-
dorferi sensu stricto, Borrelia afzelii and Borrelia
garinii [8,9]. Three stages of the disease can be
distinguished: early localised, early disseminated,
and late persistent. Diagnosis of Lyme borreliosis
on the basis of clinical symptoms is difﬁcult, as
this disease can mimic a wide range of disorders
[7]. Laboratory tests, such as culture, genomic
ampliﬁcation and serology, are therefore fre-
quently necessary. Culture is only of value with
biopsy samples of skin lesions, and is seldom
positive with cerebrospinal ﬂuid and plasma
samples [10], while molecular techniques lack
sensitivity, and are only superior to culture for
joint ﬂuid analysis [10]. Thus, laboratory diagno-
sis relies mostly on detecting a serological
response [11–13].
Accurate tests with a high predictive value are
of great importance during the early phases of the
disease, as a short course of antibiotics adminis-
tered at that time may be curative [7,14]. A delay
in the diagnosis increases the risk of protracted
symptoms, with an uncertain outcome, even after
prolonged courses of antibiotics [7]. Current
guidelines for Lyme serological testing in the
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USA and Europe rely on a two-tiered approach in
which sera are ﬁrst screened with a sensitive
enzyme immunoassay (EIA), with positive results
conﬁrmed by western immunoblotting [11,13].
This approach improves speciﬁcity, but is expen-
sive and technically difﬁcult, and the ﬁnal inter-
pretation requires previous experience [10,15].
For these reasons, replacement of the two-tiered
protocol with a sensitive, speciﬁc, objective and
less expensive test is warranted.
In recent years, a substantial effort has been
made to develop new serological tests using
synthetic and recombinant antigens [16–18]. How-
ever, tests that have optimal predictive values in
the USA appear to be of limited use in Europe,
since only B. burgdorferi sensu stricto is present in
the USA, whereas all three Borrelia subspecies are
encountered in Europe [19–21]. However, new
serological tests that could also be of value in
Europe have now been made available [22]. The
aim of the present study was to assess the
diagnostic performance of new commercially
available assays for the detection of IgM and
IgG antibodies against B. burgdorferi in samples
from European cases of early localised and early
disseminated Lyme borreliosis. Clinically deﬁned
criteria were used, in combination with a positive
test result in a recombinant immunoblot, as the
reference standard to calculate sensitivity [23].
Speciﬁcity was determined by analysing sera
from patients with infections mimicking Lyme
disease, or with conditions that are known to
interfere with the assay. The study also evaluated
whether a single test or a combination of tests
could replace the current two-tiered approach.
MATERIALS AND METHODS
Patient samples
Human serum samples were obtained from a panel of 23
patients with early localised cutaneous Lyme disease, compri-
sing 22 patients with erythema migrans and one with a
lymphocytoma, and a second panel of 22 patients with early
disseminated Lyme disease, comprising patients with arthritis
(n = 2), cranial neuritis (n = 9), radiculoneuropathy (n = 3),
erythema migrans with clinical signs of dissemination (n = 7)
and polyneuropathy (n = 1). These patients were admitted to
the Maastricht University Hospital between 1 January 2002
and 31 December 2004. Patients from the ﬁrst panel were all
positive in the IgM blot assay, and 12 were also positive in the
IgG blot assay. Other causes of symptoms were excluded for
patients belonging to the second panel; all samples were
IgG-positive and 13 were also IgM-positive in the blot assays,
except that from a patient with a bilateral facial palsy, for
whom the blot was both IgM- and IgG-negative, but who had a
documented cerebrospinal ﬂuid pleocytosis and intrathecal
antibodies that were detected with an IgG EIA (Dako,
Glostrup, Denmark).
Speciﬁcity was calculated with a patient control group
comprising 40 patients with disorders known to interfere with
Borrelia serology and ⁄or to resemble Lyme disease clinically:
ten patients with acute Epstein–Barr virus (EBV) infection, ten
with acute cytomegalovirus (CMV) infection, ten with syphilis,
and ten with rheumatoid factor positivity.
IgM and IgG immunoassays
Detection of IgM and IgG antibodies was compared using ﬁve
commercially available enzyme immunoassays: (1) QuickEL-
ISA C6 Borrelia kit (Immunetics, Boston, MA, USA); (2) IDEIA
B. burgdorferi IgM; (3) IDEIA B. burgdorferi IgG (Dako); (4)
B. burgdorferi second-generation IgM; and (5) B. burgdorferi
second-generation IgG (Serion, Wurzburg, Germany). All kits
were used according to the instructions of their respective
manufacturers. Assay characteristics are listed in Table 1.
Borderline results were considered to be positive for the
calculation of sensitivity and speciﬁcity.
Western immunoblot
The Borrelia recomBlot IgM and IgG assay (Mikrogen, Mar-
tinsried, Germany) is an immunoblot assay that uses recom-
binant proteins. The antigens used are OspA, OspC, p100, p39,
p18 (decorin-binding protein A), p41 (ﬂagellin), and a speciﬁc
internal part of the p41 antigen. The blot was performed
according to the instructions of the manufacturer.
Statistics
Sensitivity was deﬁned as true-positives ⁄ (true-positives plus
false-negatives), and speciﬁcity was deﬁned as true-negat-
ives ⁄ (true-negatives + false-positives). Graph Pad Prism v.4.0
for Windows was used for statistical analysis.
Table 1. Characteristics of the enzyme immunoassays for the detection of IgM and ⁄ or IgG antibodies against Borrelia
burdorferi
Test EIA B. burgdoferi subspecies Preabsorptiona Antigen Incubation time (min)
Dako IgM l Capture B. afzelii No Puriﬁed p41 130
Dako IgG Indirect B. afzelii No Puriﬁed p41 130
Serion IgM Indirect B. afzelii B. garinii Yes Whole-cell lysate rec p41 and p100 120
Serion IgG Indirect B. afzelii B. garinii Yes Whole-cell lysate rec p41 and p100 120
Immunetics IgM + IgG l Capture B. afzelii B. garinii B. burgdorferi No Synthetic peptide C6 30
aPreabsorption with Treponema phagedenis.
EIA, enzyme immunoassay.
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RESULTS
IgM enzyme immunoassay
The sensitivities of the Serion, Dako and Immu-
netics EIAs were evaluated for the detection of
Borrelia IgM in all serum samples with IgM
reactivity in the blot (Table 2). This included the
23 patients with localised Lyme disease and 13
patients with the disseminated form of the dis-
ease. The symptoms of these latter 13 patients
were heterogeneous and consisted of cranial
neuritis (n = 5), arthritis (n = 2), erythema mi-
grans with signs of dissemination (n = 3) and
radiculopathy (n = 3). In the localised and the
disseminated phase, sensitivities of 91% and
85%, respectively, for the Serion EIA, and 91%
and 85%, respectively, for the Immunetics assay,
were calculated. These were signiﬁcantly higher
than the corresponding Dako EIA sensitivities of
61% and 69%, respectively.
The speciﬁcity for each assay was determined
by analysing 40 sera from patients with an acute
EBV or CMV infection, or who were positive for
syphilis or rheumatoid factor, each of which are
conditions that are well-known to cause cross-
reactivity. Speciﬁcity was lowest for the Serion
assay, compared with the Dako and Immunetics
assays, mainly because of positive results with
EBV, CMV and syphilis, with speciﬁcities of 20%,
60% and 40%, respectively, whereas the Serion
assay maintained a speciﬁcity of 90% with rheu-
matoid factor positivity. In the Dako EIA, only
EBV, CMV and syphilis caused false-positive
results, with speciﬁcities of 40%, 90% and 80%,
respectively. The Immunetics EIA showed a
speciﬁcity of 90–100% for all other conditions,
except for acute EBV infection, which decreased
the speciﬁcity to 80%.
Data were expressed as the test value divided
by the manufacturers’ deﬁned assay cut-offs in
order to assess the discriminatory power of the
three evaluated IgM EIAs between the control
group (n = 40) and all IgM-positive patient
samples (n = 36) (Fig. 1A). The geometric mean
values of these ratios for the Serion, Dako and
Immunetics assay determined in the control
group were 0.92 (95% CI 0.64–1.32), 0.94
(95% CI 0.69–1.28) and 0.25 (95% CI 0.21–0.31),
respectively, compared with 2.33 (95% CI
1.72–3.16), 2.36 (95% CI 0.41–3.93) and 6.65
(95% CI 4.17–10.61), respectively, in the patient
Table 2. Sensitivity and speciﬁcity of three enzyme immunoassays for the detection of Borrelia burgdorferi IgM antibodies
in early localised and disseminated Lyme disease
Assay
Sensitivity % (95% CI) Speciﬁcity % (95% CI)
Localised (n = 23) Disseminated (n = 13) Total (n = 36) EBV (n = 10) CMV (n = 10) RF (n = 10) TP (n = 10) Total (n = 40)
Serion IgM 91 (87–96) 85 (81–89) 89 (85–93) 20 (18–22) 60 (56–63) 90 (86–94) 40 (37–43) 52 (49–56)
Dako IgM 61 (57–64) 69 (66–63) 64 (60–67) 40 (37–43) 90 (96–100) 100 (96–100) 80 (76–84) 78 (74–81)
Immunetics 91 (87–96) 85 (81–89) 89 (85–93) 80 (76–84) 100 (96–100) 100 (96–100) 90 (86–94) 92 (88–97)
EBV, positive for Epstein–Barr virus; CMV, positive for cytomegalovirus; RF, positive for rheumatoid factor; TP, positive for syphilis.
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Fig. 1. Results of the Borrelia burgdorferi IgM enzyme
immunoassays (EIAs) (A) and IgG EIAs (B) in sera from
controls (n = 40) and Lyme disease patients (n = 36 for
IgM results, n = 34 for IgG results). The levels of positivity
for test values ⁄ cut-off values ‡ 1 are shown by a broken
line. Geometric means are depicted for each assay by a
solid line.
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group. Relative to the control samples, the ratios
of the patient samples were 2.53-, 2.51- and 26.6-
fold higher using the Serion, Dako and Immunet-
ics assays, respectively. The inter-assay coefﬁ-
cients of variation were determined for the Dako
and Serion IgM assays by analysing the positive
control samples delivered with the kit, and were
found to be 9% (n = 23) and 7% (n = 21), respect-
ively.
IgG immunoassay
The sensitivities of the Serion IgG, Dako IgG
and Immunetics EIAs for detecting Borrelia IgG
were evaluated with sera collected from 12
patients with early localised Lyme disease, and
from 22 patients with the disseminated form of
the disease (Table 3). IgG positivity was con-
ﬁrmed for each sample with the immunoblot,
except for one patient with neuroborreliosis,
who nevertheless fulﬁlled the diagnostic criteria
of the disease. At the localised stage, a sensi-
tivity of 92% was obtained with the Immunetics
EIA, which was superior to the sensitivities of
83% and 42% obtained with the Serion and
Dako EIAs, respectively. The Immunetics and
Serion EIAs showed an equivalent high sensi-
tivity of 91% during the disseminated phase of
Lyme disease, whereas the Dako EIA reached a
sensitivity of only 59%. The Immunetics assay
failed to detect IgG in two patients. The ﬁrst
patient had a radiculopathy and a history of a
non-treated erythema migrans, and showed
strong and weak reactivity in the Serion and
Dako assays, respectively. The second patient,
presenting with a bilateral facial palsy, showed
no reactivity in the Serion and Immunetics
assays, but showed IgM with the Serion and
Dako assays. The Serion assay also failed to
detect IgG in a child presenting with a bilateral
facial palsy, pleiocytosis in the cerebrospinal
ﬂuid, intrathecal IgG antibody synthesis (detec-
ted by the Dako assay), and a strong serum
reactivity with the Immunetics assay. Neverthe-
less, a high IgM antibody titre was detected in
this patient by the Serion assay. The Dako assay
failed to detect IgG in nine patients presenting
with arthritis (n = 1), cranial neuritis (n = 4),
erythema migrans with clinical evidence of
dissemination (n = 3), and polyneuropathy
(n = 1). All nine patients showed reactivity in
the Immunetics and Serion IgG assays, but the
Dako IgM assay remained negative for two of
these patients.
Speciﬁcity was assessed by measuring reactiv-
ity in 40 samples from patients with an acute
CMV and EBV infection, or who were positive for
syphilis or rheumatoid factor (Table 3). A specif-
icity of 100% was achieved by the Dako assay.
The Serion assay had a high speciﬁcity of 90–
100%, except for patients with syphilis, which
caused a drop in the overall speciﬁcity to 80%.
The Immunetics EIA also had a speciﬁcity of 90–
100%, except for patients with an acute EBV
infection, which decreased the overall speciﬁcity
to 80%.
To assess the discriminatory ability of the
different EIAs (Fig. 1B), the geometric mean of
the test value was divided by the cut-off of each
assay for the patient (n = 34) and the control
group (n = 40). The geometric mean values of
these ratios with the Serion, Dako and Immune-
tics assays for the control group were 0.26
(95% CI 0.18–0.38), 0.81 (95% CI 0.80–0.82) and
0.25 (95% CI 0.21–0.31), respectively, compared
with 3.36 (95% CI 2.32–4.88), 1.77 (95% CI 1.2–
2.6) and 7.53 (95% CI 4.74–11.95), respectively,
for the patient group. Relative to the control
samples, the ratios of the patient samples were
12.9-, 2.2- and 30.1-fold higher for the Serion,
Dako and Immunetics EIAs, respectively. The
inter-assay coefﬁcients of variation for the Serion
IgG, Dako IgG and Immunetics assays, obtained
by analysing the positive control samples deliv-
ered with the kit, were 12% (n = 21), 13% (n = 23)
and 13% (n = 15), respectively.
Table 3. Sensitivity and speciﬁcity of enzyme immunoassays for the detection of Borrelia burgdorferi IgG antibodies in early
localised and disseminated Lyme disease
Assay
Sensitivity % (95% CI) Speciﬁcity % (95% CI)
Localised (n = 12) Disseminated (n = 22) Total (n = 34) EBV (n = 10) CMV (n = 10) RF (n = 10) TP (n = 10) Total (n = 40)
Serion IgG 83 (79–87) 91 (87–95) 88 (84–92) 90 (86–94) 100 (96–100) 100 (96–100) 80 (76–84) 92 (88–97)
Dako IgG 42 (39–44) 59 (56–62) 53 (50–56) 100 (96–100) 100 (96–100) 100 (96–100) 100 (96–100) 100 (96–100)
Immunetics 92 (87–96) 91 (87–95) 91 (87–95) 80 (76–84) 100 (96–100) 100 (96–100) 90 (86–94) 92 (88–97)
EBV, positive for Epstein–Barr virus; CMV, positive for cytomegalovirus; RF, positive for rheumatoid factor; TP, positive for syphilis.
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Combined IgM and IgG antibody testing
Overall, a combination of the IgG and IgM assays
showed increased sensitivity compared with the
corresponding IgM and IgG tests considered in
isolation. However, the improved sensitivity was
at the expense of speciﬁcity (Table 4). The best
combination of speciﬁcity and sensitivity was
achieved by the Immunetics assay, with a sensi-
tivity of 91% and a speciﬁcity of 92% in samples
with either IgM or IgG positivity or both (Table 4).
Analysis of the receiver operating characteristic
curve for the Immunetics assay indicated that
increasing the cut-off level from 0.12 to 0.38 (data
not shown) decreased the sensitivity to 80%while
achieving a speciﬁcity of 100% (Table 4).
A sequential test protocol to restrict the
number of conﬁrmatory immunoblots
Based on the above data, a model of sequential
testing was constructed in which the Immunetics
assay was used as a screening test. Referring to
the speciﬁcity data, a positive Immunetics assay
with an OD of 0.12–0.38 is conﬁrmed with an
immunoblot, whereas an OD exceeding 0.38 is
considered to be true-positive for the presence of
antibodies to B. burgdorferi (Fig. 2). If the Immu-
netics assay is negative, testing of a follow-up
serum or the Serion IgG and IgM tests should be
performed (Fig. 2). This approach should reduce
the total number of blots from 100% to 20% in a
patient population with localised or disseminated
Table 4. Overall sensitivity and speciﬁcity for the detection of Borrelia burgdorferi IgM and ⁄ or IgG antibodies in early
localised and disseminated Lyme disease
Assay
Sensitivity % (95% CI) Speciﬁcity % (95% CI)
Localised (n = 23) Disseminated (n = 22) Total (n = 45) EBV (n = 10) CMV (n = 10) RF (n = 10) TP (n = 10) Total (n = 40)
Serion IgG + Serion IgM 100 (96–100) 100 (96–100) 100 (96–100) 20 (18–22) 60 (56–63) 90 (86–94) 30 (28–32) 50 (47–53)
Dako IgG + Dako IgM 78 (74–82) 91 (87–95) 84 (80–88) 40 (37–43) 90 (96–100) 100 (96–100) 80 (76–84) 78 (74–81)
Immunetics 91 (87–96) 91 (87–95) 91 (87–95) 80 (76–84) 100 (96–100) 100 (96–100) 90 (86–94) 92 (88–97)
Immunetics results with OD > 0.38 78 (74–82) 82 (78–86) 80 (76–84) 100 (96–100) 100 (96–100) 100 (96–100) 100 (96–100) 100 (96–100)
EBV, positive for Epstein–Barr virus; CMV, positive for cytomegalovirus; RF, positive for rheumatoid factor; TP, positive for syphilis; OD, optical density.
Immunetics assay
Localised and disseminated Lyme 
disease n = 45
Positive Immunetics
n = 41
91%
Negative Immunetics
n = 4
9%
Immunetics
OD > 0.38
n = 36
80%
Immunetics
OD 0.12–0.38
n = 5
B. burgdorferi antibodies
present 
Blot confirmation
Serion IgG and/or
IgM positive
n = 4 
Blot confirmation
Total blot confirmations required
n = 9
20%
Fig. 2. Borrelia burgdorferi antibody testing in patients with localised and disseminated Lyme disease: results for serial
testing reaching 100% sensitivity and 100% speciﬁcity in comparison with use of the immunoblot as the reference
standard.
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Lyme disease, while preserving 100% sensitivity
and speciﬁcity.
DISCUSSION
Unlike Europe, where the three pathogenic sub-
species of B. burgdorferi that cause Lyme disease
can be found, the only organism associated with
Lyme disease in the USA is B. burgdorferi senso
stricto [8,9,21]. This makes laboratory diagnosis in
Europe more complicated than in the USA, and
serodiagnostic tests should therefore include
either antigens of the different subspecies or
shared antigens. The Dako assay is the test used
most widely in The Netherlands, and is based on
puriﬁed p41 ﬂagellin, an antigen that shows little
variation among the different B. burgdorferi sub-
species. The Serion assay uses recombinant and
puriﬁed whole-cell lysate proteins that, theoretic-
ally, detect all Borrelia spp. The Immunetics assay
relies on a synthetic peptide called C6. The
structure of this peptide is based on the 26-mer
conserved region (IR 6) of the variable surface
antigen of B. burgdorferi VlsE, which is conserved
among all pathogenic subspecies of B. burgdorferi
[17,24]. The Immunetics assay makes no distinc-
tion between IgM and IgG antibodies. Accord-
ingly, data obtained by the other two EIA assays
with respect to IgM or IgG were compared with
those from the Immunetics assay for each anti-
body subclass separately. In addition, the com-
bined IgM and IgG results of the Immunetics
assay were compared with the combined IgM and
IgG results of the Serion and Dako assays.
First, the sensitivity of the three assays was
assessed for the detection of IgM and ⁄ or IgG to
B. burgdorferi in well-deﬁned sera from patients at
the early localised and early disseminated stages
of the disease, using the immunoblot as reference.
The selection criteria used may have excluded
samples with low antibody titre, as the immuno-
blot has a lower sensitivity [25]. However, this
selection bias affected all tests equally, and would
preclude their improved performance only in
comparison with the immunoblot. The Immunet-
ics EIA showed the highest sensitivity (> 90%) for
the detection of IgM and ⁄ or IgG at the localised
stage of infection. This ﬁnding is consistent with
data from monkeys infected experimentally,
which indicated an IgG response against the C6
peptide in 70% and 100% of the monkeys at 3 and
6 weeks after inoculation, respectively [24]. In
addition, a sensitivity of 83% in European
patients with erythema migrans was reported
with a home-made C6 immunoassay [22].
In recent Finnish [26] and Italian [27] studies,
the Immunetics C6 assay had sensitivities of only
64% and 62%, respectively. The ﬁrst study
attempted only to validate the methodological
performance of the assay without deﬁning the
clinical criteria of borreliosis. The absence of
clinical information deﬁning the activity of the
disease may explain the discrepancy with the
present results. In addition, there is an ongoing
debate concerning the validity of the C6 assay as a
marker for the outcome of therapy in Lyme
disease patients [28,29]. In the second study [27],
the difference in sensitivity can be attributed to
either a different reference standard for Lyme
diagnosis, or to the composition of the patient
group, which was limited to cases with erythema
migrans. The Serion IgM and IgG EIAs both
contain antigens, such as OspC and p41, which
are able to elicit an early and intense antibody
response [30–32]; as such, both assays yielded
acceptable sensitivities in the present patient
group of 91% and 83%, respectively, at the
cutaneous stage. Surprisingly, the Dako IgM and
IgG EIAs showed sensitivities of only 61% and
42% during the localised stage. Comparison of
these data with a previous study involving
European samples showed similar sensitivities
for the Dako IgM assay, whereas the present
study revealed 20% lower sensitivity for the Dako
IgG test [25]. At the disseminated stage, similar
results were obtained with the Serion and Immu-
netics EIA for the detection of both IgM and IgG
(sensitivities of 88–91%). In this patient group, the
Dako IgG EIA had a sensitivity of only 59%.
The speciﬁcity of an assay is another important
factor in the serodiagnosis of Lyme disease. An
intention to increase the sensitivity by inclusion of
multiple antigens may lead to overdiagnosis
because of potential similarity with other non-
Borrelia proteins. Typical examples are the 41-kDa
ﬂagellin, an antigen that has shown cross-reactiv-
ity with other spirochaetes [33], and the 66-, 68-,
71- and 73-kDa antigens, which are homologues
to bacterial heat-shock proteins [34]. Therefore,
US and European guidelines still recommend
conﬁrmation of a positive or an equivocal EIA
result by western blotting [11,13,35]. However,
the C6 antigen has a unique protein sequence [17],
and home-made C6 EIAs also have a high
Smismans et al. Immunoassays for B. burgdorferi 653
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 648–655
speciﬁcity [24]. Goossens et al. [25] recommended
assessing speciﬁcity by using sera from patients
with infections mimicking Lyme disease instead
of using healthy control samples. Accordingly,
the present study used a patient control group
with disorders that are prone to interfere with
Borrelia antibody testing, including recent EBV
and CMV infections, rheumatoid arthritis and
syphilis. The speciﬁcity for the three IgG EIAs
was comparable (92–100%), but the Dako IgM
assay had a speciﬁcity of 78%, and the Serion IgM
EIA had an even lower speciﬁcity of 50%. Cross-
reactive IgM responses with the 41-kDa ﬂagellin
included in the Serion and Dako EIAs are known
to reduce speciﬁcity; the same is true for the OspC
antigen, which is also present in the Serion assay
[36]. The highest discriminatory power between
Lyme patients and control samples was achieved
with the Immunetics assay for both IgM and IgG
determination. Between-run coefﬁcients of vari-
ation were comparable and acceptable for all the
assays investigated, with a maximum variation of
13%.
The use of an EIA–western blot two-test proto-
col certainly improves the speciﬁcity obtained
with the EIA alone, but may result in a loss of
sensitivity [25]. In addition, this two-tiered ap-
proach is costly, time-consuming and requires
technical experience. Thus, a screening strategy
that omits the conﬁrmatory immunoblot in as
many cases as possible, while attaining compar-
able levels of sensitivity and speciﬁcity, is highly
desirable. Based on the results obtained in the
present study, ﬁrst-step screening with the Im-
munetics EIA is recommended. Only low-titre
positive Immunetics results (OD between 0.12
and 0.38) require an immunoblot to distinguish
false-positives, whereas results with an OD >0.38
have 100% speciﬁcity, thus obviating any need
for conﬁrmation. If the Immunetics assay is
negative, a follow-up serum can be requested, or
the Serion IgM and IgG assay can be performed.
This approach improves cost-effectiveness and
circumvents the high inter-laboratory variation
that occurs as a consequence of differences in the
methodology and interpretation of immunoblot-
ting [37]. A similar method of combined analysis
for the detection of B. burgdorferi IgG in a Finnish
population of Lyme disease patients and healthy
blood donors, using the Recomwell Borrelia IgG
assay (Mikrogen, Martinsreid, Germany) and the
C6 Immunetics assay, resulted in a 44% decrease
in workload, while preserving a sensitivity of
91% and a speciﬁcity of 99% [26].
In conclusion, the Immunetics assay, used as a
single test, gave the best performance of the ﬁve
assays evaluated for the diagnosis of European
Lyme disease patients. The assay requires no
pre-treatment, can be fully automated, and offers
high sensitivity and speciﬁcity for detection of
early Lyme disease, combined with low variation
and a high signal-to-noise ratio. The use of a
synthetic peptide shows promise for quality
assurance. These advantages make the Immunet-
ics assay suitable for use as a ﬁrst-tier test for
B. burgdorferi antibody detection. Prospective
studies are underway to validate these ﬁndings.
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